This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
by Zacks Equity Research
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Pre-Markets in Red on Mid-East Concerns, Q3 Earnings in Focus
by Zacks Equity Research
U.S. stock futures are trading lower as the geopolitical conflicts between Israel and Palestine-based terrorist group Hamas heightened.
Abbott (ABT) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 3.60%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Should You Buy Abbott (ABT) Ahead of Earnings?
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
(ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.87 in the latest trading session, marking a +0.75% move from the prior day.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
HLN vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. ABT: Which Stock Is the Better Value Option?
(ABT) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Abbott (ABT) closed at $96.20 in the latest trading session, marking a +0.58% move from the prior day.
The Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & Nephew
by Zacks Equity Research
Abbott Laboratories, Koninklijke Philips and Smith & Nephew are included in this Analyst Blog.
3 Medical Product Stocks With Solid Dividend Yield: ABT & Others
by Indrajit Bandyopadhyay
Here we pick three stocks, Abbott Laboratories (ABT), Koninklijke Philips (PHG) and Smith & Nephew SNATS (SNN) from the Medical - Products industry, with a solid five-year dividend growth history.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $96.85, marking a -1.29% move from the previous day.
Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales
by Zacks Equity Research
Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.
After Plunging -8.5% in 4 Weeks, Here's Why the Trend Might Reverse for Abbott (ABT)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Abbott (ABT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy
by Zacks Equity Research
Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy are part of the Zacks top Analyst Blog.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $95.53 in the latest trading session, marking a -0.73% move from the prior day.
Top Stock Reports for Alphabet, Exxon Mobil & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why
by Zacks Equity Research
Prestige Consumer (PBH) benefits from a robust healthcare brand portfolio and solid demand.
Here's Why Investors Should Invest in Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.
5 Dividend Aristocrats to Buy as Things Look Dicey for Wall Street
by Tirthankar Chakraborty
As stocks are subjected to bouts of volatility, place bets on dividend aristocrats like Caterpillar (CAT), Abbott Laboratories (ABT), McDonald's (MCD), Aflac (AFL) and Automatic Data Processing (ADP) for steady income.